-
1 Comment
Guilin Sanjin Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 3.2% below its 200 day moving average.
From a valuation standpoint, the stock is 50.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.
Guilin Sanjin Pharmaceutical Co., Ltd's total revenue sank by 32.6% to $346M since the same quarter in the previous year.
Its net income has increased by 3.7% to $64M since the same quarter in the previous year.
Finally, its free cash flow grew by 506.8% to $21M since the same quarter in the previous year.
Based on the above factors, Guilin Sanjin Pharmaceutical Co., Ltd gets an overall score of 3/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100000DY9 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Target Price | 15.92 |
|---|---|
| Market Cap | 8B |
| PE Ratio | 15.17 |
| Dividend Yield | 6.2% |
| Beta | 0.45 |
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand; and Naomaitai capsules, etc. It also produces TCM preparations. Guilin Sanjin Pharmaceutical Co., Ltd. was founded in 1967 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002275.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
